DiaSorin have launched the LIAISON Campylobacter test for the market outside the US, completing their bacterial stool-testing panel that includes Clostridium, EHEC, H. pylori.

The LIAISON Campylobacter is the 8th test launched as part of our stool-testing offer and is one of the most frequently occurring bacterial agents of gastroenteritis. The true incidence of gastroenteritis due to Campylobacter is poorly known, particularly in emerging markets; studies in high-income countries have estimated the annual incidence at between 4.4 and 9.3 per 1000 population. In the US an estimated 2 million cases of Campylobacter enteritis occur annually, accounting for 5-7% of cases of gastroenteritis. At the moment laboratories mainly use fecal-culture to diagnose Campylobacter but that can take 3 days and requires careful handling of the sample, problems that the new LIAISON Campylobacter test will solve. It is important to diagnose Campylobacter in time, considering that 36% of patients with severe Campylobacter infections develop inflammatory chronic bowel syndrome (IBS) within 1–2 years. Until now, Campylobacter has been considered a lower problematic, but the technology developed by DiaSorin will allow laboratories and therefore doctors to answer in due time with an appropriate treatment in the early stage of the disease.

Visit the Diasorin website for more information